Physician profile
John Matthew Moore
NPI 1205009180
$10,916.81
in general payments reported to CMS, 2019-2025
32 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $5,313 · 2021: $529 · 2022: $907 · 2023: $938 · 2024: $917 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808 · Education: $90.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.32 |
| Education | $90.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu A/S | $4,906.92 | 2020 | |
| Abbvie INC. | $2,119.72 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,216.59 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $527.91 | 2019-2025 | |
| Janssen Biotech, INC. | $341.13 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $279.13 | 2019-2022 | |
| Celgene Corporation | $212.70 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $197.40 | 2021-2023 | |
| Ardelyx, INC. | $136.26 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $128.36 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $124.17 | 2019-2025 | Rebyota |
| Celltrion USA INC. | $110.07 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $96.00 | 2023-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Evoke Pharma, INC. | $49.68 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $45.99 | 2019-2022 | |
| Revance Therapeutics, INC. | $38.95 | 2024 | Daxxify |
| Ironwood Pharmaceuticals, INC | $30.41 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $28.38 | 2021-2022 | |
| Madrigal Pharmaceuticals | $28.27 | 2025 | Rezdiffra |
| Genzyme Corporation | $27.58 | 2024 | |
| Daiichi Sankyo INC. | $26.91 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $24.58 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $23.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $21.33 | 2025 | Zenpep |
| Shire North American Group INC | $20.03 | 2019 | |
| Medtronic, INC. | $16.40 | 2024 | Gi Genius |
| Organon LLC | $15.67 | 2025 | Hadlima, Renflexis |
| Redhill Biopharma INC. | $13.40 | 2020 | |
| Ucb, INC. | $11.93 | 2019 | |
| Romark Laboratories, Lc | $6.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.